search icon
mnov-img

MediciNova Inc, Common Stock

MNOV

NMQ

$1.39

-$0.03

(-2.11%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$69.16M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
2.77K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.46
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.12 L
$2.55 H
$1.39

About MediciNova Inc, Common Stock

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameMNOVSectorS&P500
1-Week Return-1.42%2.19%1.86%
1-Month Return-8.55%-5.18%6.39%
3-Month Return-15.24%-10.56%-0.73%
6-Month Return-41.6%-9.48%-2.29%
1-Year Return4.51%-5.95%12.88%
3-Year Return-42.8%0.73%42.84%
5-Year Return-74.35%30.6%93.02%
10-Year Return-64.81%77.03%179.63%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue4.00M4.04M-1.00M-[{"date":"2020-12-31","value":99.07,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":24.77,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue21.34K-212.43K20.30K21.08K[{"date":"2020-12-31","value":10.05,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":9.55,"profit":true},{"date":"2024-12-31","value":9.92,"profit":true}]
Gross Profit(21.34K)4.04M(212.43K)1.00M(21.08K)[{"date":"2020-12-31","value":-0.53,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-5.26,"profit":false},{"date":"2023-12-31","value":24.77,"profit":true},{"date":"2024-12-31","value":-0.52,"profit":false}]
Gross Margin(0.53%)100.00%-100.00%-[{"date":"2020-12-31","value":-0.53,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses14.18M14.25M14.63M10.90M12.65M[{"date":"2020-12-31","value":96.92,"profit":true},{"date":"2021-12-31","value":97.43,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":74.51,"profit":true},{"date":"2024-12-31","value":86.5,"profit":true}]
Operating Income(14.18M)(10.22M)(14.63M)(9.90M)(12.68M)[{"date":"2020-12-31","value":-1417832300,"profit":false},{"date":"2021-12-31","value":-1021581200,"profit":false},{"date":"2022-12-31","value":-1462864900,"profit":false},{"date":"2023-12-31","value":-990026500,"profit":false},{"date":"2024-12-31","value":-1267533100,"profit":false}]
Total Non-Operating Income/Expense683.96K227.75K1.37M3.17M3.30M[{"date":"2020-12-31","value":20.71,"profit":true},{"date":"2021-12-31","value":6.9,"profit":true},{"date":"2022-12-31","value":41.55,"profit":true},{"date":"2023-12-31","value":95.89,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(13.86M)(10.13M)(14.07M)(8.57M)(11.04M)[{"date":"2020-12-31","value":-1385554500,"profit":false},{"date":"2021-12-31","value":-1013168400,"profit":false},{"date":"2022-12-31","value":-1406626100,"profit":false},{"date":"2023-12-31","value":-856846900,"profit":false},{"date":"2024-12-31","value":-1104401200,"profit":false}]
Income Taxes(1.65K)2.57K2.82K3.05K5.54K[{"date":"2020-12-31","value":-29.76,"profit":false},{"date":"2021-12-31","value":46.38,"profit":true},{"date":"2022-12-31","value":50.97,"profit":true},{"date":"2023-12-31","value":55.03,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes(13.85M)(10.13M)(14.07M)(8.57M)(11.05M)[{"date":"2020-12-31","value":-1385389700,"profit":false},{"date":"2021-12-31","value":-1013425200,"profit":false},{"date":"2022-12-31","value":-1406908300,"profit":false},{"date":"2023-12-31","value":-857151600,"profit":false},{"date":"2024-12-31","value":-1104954900,"profit":false}]
Income From Continuous Operations(13.85M)(10.13M)(14.07M)(8.57M)(11.05M)[{"date":"2020-12-31","value":-1385389700,"profit":false},{"date":"2021-12-31","value":-1013425200,"profit":false},{"date":"2022-12-31","value":-1406908300,"profit":false},{"date":"2023-12-31","value":-857151600,"profit":false},{"date":"2024-12-31","value":-1104954900,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(13.85M)(10.13M)(14.07M)(8.57M)(11.05M)[{"date":"2020-12-31","value":-1385389700,"profit":false},{"date":"2021-12-31","value":-1013425200,"profit":false},{"date":"2022-12-31","value":-1406908300,"profit":false},{"date":"2023-12-31","value":-857151600,"profit":false},{"date":"2024-12-31","value":-1104954900,"profit":false}]
EPS (Diluted)(0.30)(0.20)(0.30)(0.18)(0.23)[{"date":"2020-12-31","value":-30,"profit":false},{"date":"2021-12-31","value":-20.4,"profit":false},{"date":"2022-12-31","value":-30.5,"profit":false},{"date":"2023-12-31","value":-18,"profit":false},{"date":"2024-12-31","value":-23,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

MNOV
Cash Ratio 17.14
Current Ratio 17.66

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

MNOV
ROA (LTM) -13.81%
ROE (LTM) -20.33%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

MNOV
Debt Ratio Lower is generally better. Negative is bad. 0.05
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.95

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

MNOV
Trailing PE NM
Forward PE NM
P/S (TTM) 82.89
P/B 1.39
Price/FCF NM
EV/R 38.74
EV/Ebitda NM
PEG NM

FAQs

What is MediciNova Inc share price today?

MediciNova Inc (MNOV) share price today is $1.39

Can Indians buy MediciNova Inc shares?

Yes, Indians can buy shares of MediciNova Inc (MNOV) on Vested. To buy MediciNova Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MNOV stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of MediciNova Inc be purchased?

Yes, you can purchase fractional shares of MediciNova Inc (MNOV) via the Vested app. You can start investing in MediciNova Inc (MNOV) with a minimum investment of $1.

How to invest in MediciNova Inc shares from India?

You can invest in shares of MediciNova Inc (MNOV) via Vested in three simple steps:

  • Click on Sign Up or Invest in MNOV stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in MediciNova Inc shares
What is MediciNova Inc 52-week high and low stock price?

The 52-week high price of MediciNova Inc (MNOV) is $2.55. The 52-week low price of MediciNova Inc (MNOV) is $1.12.

What is MediciNova Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of MediciNova Inc (MNOV) is 1.39

What is the Market Cap of MediciNova Inc?

The market capitalization of MediciNova Inc (MNOV) is $69.16M

What is MediciNova Inc’s stock symbol?

The stock symbol (or ticker) of MediciNova Inc is MNOV

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top